Physician profile
John L Schwartz
NPI 1053315978
$600.29
in general payments reported to CMS, 2019-2025
11 companies · $34.24 in 2025
The $34.24 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $55.13 · 2021: $66.29 · 2022: $163 · 2023: $15.36 · 2024: $107 · 2025: $34.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $156.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $254.45 | 2021-2024 | Pressurewire |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $87.15 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $76.41 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $45.57 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $35.37 | 2019-2024 | |
| Chiesi USA, INC. | $21.45 | 2019 | |
| Microtransponder, INC. | $20.41 | 2025 | |
| Astellas Pharma US INC | $17.29 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.04 | 2024 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $13.92 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $13.23 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.